Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.23750/abm.v91i3.10391 http://scihub22266oqcxt.onion/10.23750/abm.v91i3.10391 32921729!7716958!32921729     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32921729&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Acta+Biomed 2020 ; 91 (3): e2020035 Nephropedia Template TP {{tp|p=32921729|t=2020. Sars-CoV-2 infection in patients with cystic fibrosis An overview |pdf=|usr=}}{{32921729}} gab.com Text Sars-CoV-2 infection in patients with cystic fibrosis An overview JO: Acta Biomed http://www.kidney.de/pget.php?&tw=1&pmid=32921729 #FOAvip The novel coronavirus SARS-CoV-2 was first identified in China in December 2019 and has since spread worldwide. People with Cystic Fibrosis (CF) have reduced survival mainly because of respiratory failure due to chronic pulmonary infections. Therefore, CF patients should be considered to have an increased risk of developing severe manifestations in case of SARS-CoV-2 infection. Surprisingly, the results of recent studies concerning SARS-CoV-2 infection in patients with CF show that in these patients the infection rate was lower than that of the general population. Various factors have been considered to explain a possible protective effect of CF against SARS-CoV-2 infection. Twit Text FOAVip Sars-CoV-2 infection in patients with cystic fibrosis An overview ????Acta Biomed http://www.kidney.de/pget.php?&tw=1&pmid=32921729 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32921729 #FOAvip English Wikipedia <ref>{{Cite pmid|32921729}}</ref> Sars-CoV-2 infection in patients with cystic fibrosis An overview #MMPMID32921729 Fainardi V; Longo F; Chetta A; Esposito S; Pisi G Acta Biomed 2020[Sep]; 91 (3): e2020035 PMID32921729show ga The novel coronavirus SARS-CoV-2 was first identified in China in December 2019 and has since spread worldwide. People with Cystic Fibrosis (CF) have reduced survival mainly because of respiratory failure due to chronic pulmonary infections. Therefore, CF patients should be considered to have an increased risk of developing severe manifestations in case of SARS-CoV-2 infection. Surprisingly, the results of recent studies concerning SARS-CoV-2 infection in patients with CF show that in these patients the infection rate was lower than that of the general population. Various factors have been considered to explain a possible protective effect of CF against SARS-CoV-2 infection. |*Betacoronavirus[MESH] |*Pandemics[MESH] |COVID-19[MESH] |Comorbidity[MESH] |Coronavirus Infections/*epidemiology[MESH] |Cystic Fibrosis/diagnosis/*epidemiology[MESH] |Humans[MESH] |Lung/*diagnostic imaging[MESH] |Pneumonia, Viral/*epidemiology[MESH] |SARS-CoV-2[MESH]Sars-CoV-2 infection in patients with cystic fibrosis An overview (epmc).pdf DeepDyve Pubget Overpricing